# US 2022/0033849 A1 · Methods for the purification of viral vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033849 A1
- Document ID: US20220033849A1
- Status: Published application
- Kind: A1
- Application number: 17/356,980
- Filed: 2021-06-24
- Published: 2022-02-03
- Earliest claimed: 2020-06-24
- Assignees: Bioverativ Therapeutics Inc.; Fondazione Telethon; Ospedale San Raffaele S.R.L.
- Applicants: Bioverativ Therapeutics Inc.; Fondazione Telethon; Ospedale San Raffaele S.R.L.
- Inventors: Mukesh Mayani; Tongyao Liu; Ayman Ismail
- Web page: https://patentgrep.com/patent/US20220033849A1

## CPC

- C12N 15/86: Viral vectors
- B01D 15/1864: {using two or more columns}
- B01D 15/363: {Anion-exchange}
- B01D 15/3804: {Affinity chromatography}
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- C12N 2740/15041: Use of virus, viral particle or viral elements as a vector
- C12N 2740/15051: Methods of production or purification of viral material
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16051: Methods of production or purification of viral material
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Viral vector production processes and methods of purifying a viral vector from a host cell are provided herein.

## Claims

### Claim 1

A method of purifying a viral vector from a host cell, the method comprising:
(i) contacting a composition comprising the viral vector and a transgene protein contaminant with a first chromatography matrix capable of selectively binding the transgene protein contaminant; and
(ii) recovering the viral vector in the flow-through of the chromatography matrix,
thereby separating the viral vector from the transgene protein contaminant.

### Claim 2 (depends on 1)

The method of claim 1, further comprising
(iii) contacting the composition comprising the viral vector and the transgene protein contaminant with a second chromatography matrix capable of selectively binding the viral vector, and
(iv) eluting the viral vector from the second chromatography matrix,
wherein steps (iii) and (iv) are performed prior to step (i).

### Claim 3 (depends on 1)

The method of claim 1, further comprising
(iii) contacting the viral vector recovered from step (ii) with a second chromatography matrix capable of selectively binding the viral vector, and
(iv) eluting the viral vector from the second chromatography matrix.

### Claim 4 (depends on 1)

The method of claim 1, wherein step (i) and (ii) are repeated multiple times.

### Claim 5 (depends on 1)

The method of claim 1, wherein step (i) is conducted in the presence of an agent that stabilizes the transgene protein contaminant and wherein the agent is CaCl2).

### Claim 6

(canceled)

### Claim 7 (depends on 3)

The method of claim 3, further comprising the step of (v) adjusting the concentration of a salt of the composition comprising the viral vector and the transgene protein contaminant to a target salt concentration.

### Claim 8 (depends on 7)

The method of claim 7, wherein step (v) is performed prior to step (i).

### Claim 9 (depends on 7)

The method of claim 7, wherein if steps (iii) and (iv) are performed prior to step (i), then step (v) is performed between steps (iv) and (i).

### Claim 10 (depends on 7)

The method of claim 7, wherein the salt is NaCl and wherein the target salt concentration is from about 0.2M to about 0.6M.

### Claim at position 11

-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein step (i) is performed by loading the first chromatography matrix with the composition comprising the viral vector and the transgene protein contaminant in a loading buffer comprising Tris-HCl buffer or phosphate buffer at a pH about 7.0 to about 7.5.

### Claim 15 (depends on 2)

The method of claim 2, wherein step (iv) is performed by eluting the viral vector from the second chromatography matrix with an elution buffer comprising Tris-HCl buffer or phosphate buffer at a pH of about 7.0 to about 7.5.

### Claim 16 (depends on 2)

The method of claim 2, further comprising the step of (vi) combining the viral vector separated from the transgene protein contaminant with one or more pharmaceutical excipients to produce a pharmaceutical composition comprising the viral vector, wherein the pharmaceutical composition is substantially free of the transgene protein contaminant, wherein step (vi) is performed after step (iv).

### Claim 17 (depends on 16)

The method of claim 16, wherein step (vi) is performed by ultrafiltration/diafiltration (UF/DF) of the viral vector separated from the transgene protein contaminant with a formulation buffer and wherein the UF/DF step comprises tangential flow filtration (TFF).

### Claim 18

(canceled)

### Claim 19 (depends on 17)

The method of claim 17, wherein the formulation buffer is a phosphate or histidine buffer comprising NaCl and sucrose.

### Claim 20 (depends on 16)

The method of claim 16, wherein the pharmaceutical composition contains less than 20% of the transgene protein contaminant present in a reference viral vector composition purified with the second chromatography matrix but not the first chromatography matrix.

### Claim at position 19

-25. (canceled)

### Claim 26 (depends on 1)

The method of claim 1, wherein the first chromatography matrix is an affinity chromatography column comprising an affinity ligand that specifically binds to the transgene protein contaminant.

### Claim at position 21

-28. (canceled)

### Claim 29 (depends on 1)

The method of claim 1, wherein the transgene protein is a clotting factor.

### Claim at position 23

-35. (canceled)

### Claim 36

A method of purifying a lentiviral vector (LVV) from a host cell, the LVV comprising a factor VIII (FVIII) transgene, the method comprising:
(i) contacting a composition comprising the LVV and a FVIII transgene protein contaminant with a first chromatography matrix capable of selectively binding FVIII transgene protein contaminant; and
(ii) recovering the LVV in the flow-through of the chromatography matrix,
thereby separating the LVV from the FVIII protein contaminant.

### Claim at position 25

-65. (canceled)

### Claim 66 (depends on 1)

A composition comprising a viral vector produced according to the method of claim 1.

### Claim 67 (depends on 66)

The composition of claim 66, wherein the composition is a pharmaceutical composition comprising the viral vector and one or more pharmaceutical excipients, and wherein the composition is substantially free of transgene protein contaminant.

### Claim at position 28

-74. (canceled)
